Redirecting to https://www.globenewswire.com/news-release/2025/08/28/3140588/0/en/TOLREMO-therapeutics-Receives-Two-FDA-Fast-Track-Designations-for-TT125-802-in-Pretreated-Advanced-or-Metastatic-NSCLC-With-Either-an-EGFR-or-a-KRAS-G12C-Mutation.html